Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from Achilles Therapeutics ( (ACHL) ).
Achilles Therapeutics announced the resignation of three members from its Board of Directors, effective December 31, 2024, as part of a planned reduction in board size. The resignations of Julie O’Neill, Michael Giordano, and Bernhard Ehmer are not due to any disagreements with the company’s operations or policies, suggesting a strategic realignment rather than internal conflict.
More about Achilles Therapeutics
Achilles Therapeutics is a biotechnology company based in the United Kingdom. The company focuses on developing precision T cell therapies targeting clonal neoantigens for the treatment of cancer.
YTD Price Performance: 1.67%
Average Trading Volume: 163,894
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $47.66M
See more data about ACHL stock on TipRanks’ Stock Analysis page.
